Clinical trials: Mealtimes
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Dementia, Alzheimer Type, Weight Loss
Partners at Meals - Respite Care and Home (PAM)
The goal of this study was to test the efficacy of a mealtime intervention in respite care centers for people with dementia and their caregivers.
- Trial name
- PAM (NCT03622814)
- Testing
- Partners at Meals, Enhanced Usual Condition
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Obesity
Healthy Home Offerings Via the Mealtime Environment (HOME) Plus
The goal of the proposed project is to see if an innovative family-based intervention can reduce childhood obesity by actively engaging the whole family in promoting healthy behaviors in the home.
- Trial name
- NCT01538615
- Testing
- HOME Plus intervention
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Type2 Diabetes
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.
- Trial name
- NCT03324776
- Testing
- Afrezza Inhalant Product
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Model Clinical Research LLC
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT03338023
- Testing
- LY2963016, Lantus®, Insulin Lispro
- Where
- 20 sites in China
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
- Trial name
- NCT02152384
- Testing
- Insulin Peglispro, Insulin Lispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Cystic Fibrosis-related Diabetes
Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin…
- Trial name
- NCT04533646
- Testing
- Insulin, Continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jagdeesh Ullal
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as…
- Trial name
- SWITCH 1 (NCT02034513)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 99 sites in United States, Poland and 1 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes
This trial is conducted in Europe. The purpose of this trial is to investigate if there is any change in the mechanism of energy expenditure (i.e.
- Trial name
- NCT00509925
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine.
- Trial name
- NCT02197520
- Testing
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives: To compare a new formulation of…
- Trial name
- NCT01658579
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Infant Obesity, Parenting
Learning to Love Mealtime Together
Infancy is an important target period for obesity prevention because once obese as an infant, the relative risk of remaining obese appears to rise with increasing age at great cost to both individuals and society.
- Conditions
- Infant Obesity, Parenting, Feeding Behavior
- Trial name
- LiTTLe Me (NCT04502979)
- Testing
- Responsive Feeding Training
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to…
- Trial name
- 4T (NCT00184600)
- Testing
- biphasic insulin aspart, insulin detemir, insulin aspart
- Where
- 63 sites in Ireland, United Kingdom
- Volunteers
- 708 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Assessment of Mealtime Bolus Insulin Behavior
The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational…
- Trial name
- NCT03368807
- Testing
- Continuous Glucose Monitoring, Insulin Lispro
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine…
- Trial name
- BEGIN™ (NCT00982228)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 91 sites in United States, France and 4 more
- Volunteers
- 629 people
- Sponsor
- Novo Nordisk A/S
Obesity, Childhood, Physical Activity
New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME
The goal of the proposed project is to see if an innovative family-based intervention can reduce childhood obesity by actively engaging the whole family in promoting healthy behaviors in the home.
- Conditions
- Obesity, Childhood, Physical Activity, Food Intake, Rural Health
- Trial name
- NU-HOME (NCT02973815)
- Testing
- NU-HOME Intervention
- Where
- United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 1 Diabetes
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a challenging medical disorder, especially in children and adolescents. In order to prevent the chronic complications of hyperglycemia, the maintenance of near-normal glycemic control must be…
- Trial name
- NCT04157738
- Testing
- Rapid-Acting Insulin, Long acting insulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University